This site is intended for health professionals only!

Published on 29 October 2008

Share this story:

High hopes for new MRSA antibiotic


A new antibiotic that shows promise in treating the superbug MRSA and related infections is poised to enter the market after phase III ASSIST trials in the US.

Intravenous iclaprim, a novel antibiotic, is reported by manufacturer Arpida to show high clinical cure rates similar to those of the comparator drug, linezolid.

The test results were gathered from the ASSIST-1 and ASSIST-2, (Arpida’s skin and skin structure infection study) pivotal Phase III studies involving a total of 991 patients.

Data from the studies also show that iclaprim exhibited a high eradication rate for MRSA (76.4%), which was comparable to that of linezolid (78.7%).

Arpida president and CEO Jürgen Raths said: “These data further support the safety and efficacy of iclaprim as a potential treatment against complicated skin and skin-structure infections.

“Arpida remains encouraged and optimistic about the potential of iclaprim for the treatment of MRSA and related infections, and looks forward to bringing iclaprim to market, providing a new treatment option for physicians.”

A new drug application will now be discussed at the meeting of the US Food and Drug Administration anti-infective drugs advisory committee on 20 November 2008.

Copyright PA Business 2008

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: